Amy Simmons
Family · Gold Canyon, AZNPI 1366953143
Payments from drug & device makers
Across 120 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$436
- AbbVie$320
- GSK$283
- AstraZeneca$225
- Amgen$156
- Boehringer Ingelheim$152
- plus $700 from 16 others
What the payments were for
- Food & beverage$2,24799%
- Education$90%
- Entertainment$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $436 |
| AbbVie | 17 | $320 |
| GSK | 15 | $283 |
| AstraZeneca | 10 | $225 |
| Amgen | 10 | $156 |
| Boehringer Ingelheim | 8 | $152 |
| Lilly USA, LLC | 9 | $144 |
| Astellas Pharma US Inc | 4 | $99 |
| Sumitomo Pharma America, Inc. | 3 | $75 |
| Exact Sciences | 3 | $60 |
| Phathom Pharmaceuticals, Inc. | 2 | $58 |
| Novartis | 3 | $57 |
| Pfizer | 2 | $35 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Abbott | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Optos, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$2,272 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $75,941 |
| MounjaroTirzepatide | 51 | $64,980 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $26,884 |
| EliquisApixaban | 19 | $24,698 |
| JardianceEmpagliflozin | 15 | $18,998 |
| XareltoRivaroxaban | 12 | $18,656 |
| GemtesaVibegron | 16 | $17,938 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $8,019 |
| Clonidine | 15 | $3,264 |
| Levothyroxine Sodium | 270 | $2,805 |
| Duloxetine Hcl | 61 | $2,412 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $2,015 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 59 | $1,956 |
| Gabapentin | 77 | $1,895 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 27 | $1,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $436 | $75,94152 claims |
| Lilly USA, LLCMounjaro | $144 | $64,98051 claims |
| GSKTrelegy Ellipta | $283 | $26,88430 claims |
| PfizerEliquis | $35 | $24,69819 claims |
| Boehringer IngelheimJardiance | $152 | $18,99815 claims |
| Johnson & JohnsonXarelto | $15 | $18,65612 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $75 | $17,93816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.
Other family in Gold Canyon
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
- Celeste FineGilbert$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.